Remdesivir, COVID-19 drug launched by Dr. Redddy’s Labortaories

Dr. Redyy’s Laboratories announced the launch of the antiviral drug Remdesivir, under the brand name Redyx in India for the treatment of COVID-19 patients. The drug is approved by the Drug Controller General of India (DCGI) for COVID-19 patients who are hospitalized and in critical condition.

The launch is part of the licensing agreement with Gilead Sciences, Inc. (Gilead) that grants Dr Reddys the right to register, manufacture and sell Remdesivir, a potential treatment for Covid-19, in 127 countries including India. The drug will be available in strength of 100 mg vial,

Advertisement

 ” The launch of Redyx reaffirms our commitment to bringing in critical medicine for patients suffering from COVID-19 in India.”. Chief Executive Officer of Branded Markets (India and Emerging Markets), Dr Reddys Laboratories, M V Ramana said. He also added that they will continue their efforts to develop products that address other significant unmet needs of patients.